Drugging unconventional targets: Insights from Huntington's disease

Trends in Pharmacological Sciences

Volumn 35, Issue 2, 2014, Pages 53-62

  Yu, Shenliang ^a   Liang, Yijian ^a   Palacino, James ^b   Difiglia, Marian ^c   Lu, Boxun ^a,c  

^a FUDAN UNIVERSITY   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antisense oligonucleotides; high throughput screening; neurodegenerative disorder; protein degradation; proteinopathies; RNA interference

Indexed keywords

ANTISENSE OLIGONUCLEOTIDES; HIGH-THROUGHPUT SCREENING; NEURODEGENERATIVE DISORDER; PROTEIN DEGRADATION; PROTEINOPATHIES; RNA INTERFERENCE;

ANIMALS; HUMANS; HUNTINGTON DISEASE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS;

EID: 84895072822     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.12.001     Document Type: Review

References (107)

1. M. Kidd et al. Senile plaque amyloid, paired helical filaments, and cerebrovascular amyloid in Alzheimer's disease are all deposits of the same protein Lancet 1 1985 278
2. M.G. Spillantini et al. Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
3. J. Sreedharan et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis Science 319 2008 1668 1672
4. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
5. F.O. Walker Huntington's disease Lancet 369 2007 218 228
6. D.I. Shirasaki et al. Network organization of the huntingtin proteomic interactome in mammalian brain Neuron 75 2012 41 57
7. L.S. Kaltenbach et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration PLoS Genet. 3 2007 e82
8. P. Harjes, and E.E. Wanker The hunt for huntingtin function: interaction partners tell many different stories Trends Biochem. Sci. 28 2003 425 433
9. E. Cattaneo et al. Normal huntingtin function: an alternative approach to Huntington's disease Nat. Rev. Neurosci. 6 2005 919 930
10. D.C. Rubinsztein, and J. Carmichael Huntington's disease: molecular basis of neurodegeneration Expert Rev. Mol. Med. 5 2003 1 21
11. M. Arrasate et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
12. A.S. Tsvetkov et al. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration Nat. Chem. Biol. 9 2013 586 592
13. A. Yamamoto et al. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66
14. S. Zeitlin et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue Nat. Genet. 11 1995 155 163
15. M.P. Duyao et al. Inactivation of the mouse Huntington's disease gene homolog Hdh Science 269 1995 407 410
16. R.L. Boudreau et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice Mol. Ther. 17 2009 1053 1063
17. R. Grondin et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum Brain 135 2012 1197 1209
18. B. Lu, and J. Palacino A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration FASEB J. 27 2013 1820 1829
19. S.Q. Harper et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. U.S.A. 102 2005 5820 5825
20. E. Rodriguez-Lebron et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice Mol. Ther. 12 2005 618 633
21. M. DiFiglia et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc. Natl. Acad. Sci. U.S.A. 104 2007 17204 17209
22. P.H. van Bilsen et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts Hum. Gene Ther. 19 2008 710 719
23. E.L. Pfister et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients Curr. Biol. 19 2009 774 778
24. Y. Zhang et al. Allele-specific silencing of mutant Huntington's disease gene J. Neurochem. 108 2009 82 90
25. J. Hu et al. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism Chem. Biol. 17 2010 1183 1188
26. K.T. Gagnon et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat Biochemistry 49 2010 10166 10178
27. J.B. Carroll et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin Mol. Ther. 19 2011 2178 2185
28. H.B. Kordasiewicz et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis Neuron 74 2012 1031 1044
29. D. Yu et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression Cell 150 2012 895 908
30. V. Drouet et al. Sustained effects of nonallele-specific Huntingtin silencing Ann. Neurol. 65 2009 276 285
31. J.L. McBride et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease Mol. Ther. 19 2011 2152 2162
32. C.A. Ross, and M.A. Poirier What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. 6 2005 891 898
33. C.A. Gutekunst et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J. Neurosci. 19 1999 2522 2534
34. N. Aronin et al. Are there multiple pathways in the pathogenesis of Huntington's disease? Phillos. Trans. R. Soc. Lond. B: Biol. Sci. 354 1999 995 1003
35. J. Leitman et al. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress Nat. Commun. 4 2013 2753
36. X. Li et al. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease J. Neurosci. 30 2010 4552 4561
37. E. Sapp et al. Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer J. Biol. Chem. 287 2012 13487 13499
38. J. Miller et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration Nat. Chem. Biol. 7 2011 925 934
39. D.J. Klionsky, and Y. Ohsumi Vacuolar import of proteins and organelles from the cytoplasm Annu. Rev. Cell Dev. Biol. 15 1999 1 32
40. V. Kirkin, and I. Dikic Role of ubiquitin- and Ubl-binding proteins in cell signaling Curr. Opin. Cell Biol. 19 2007 199 205
41. B. Levine, and G. Kroemer Autophagy in the pathogenesis of disease Cell 132 2008 27 42
42. M. Komatsu et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice Cell 131 2007 1149 1163
43. G. Bjorkoy et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death J. Cell Biol. 171 2005 603 614
44. M. Filimonenko et al. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy Mol. Cell 38 2010 265 279
45. C. Settembre et al. TFEB links autophagy to lysosomal biogenesis Science 332 2011 1429 1433
46. T. Tsunemi et al. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function Sci. Transl. Med. 4 2012 142ra197
47. N.R. Jana et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes J. Biol. Chem. 280 2005 11635 11640
48. P.O. Bauer et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein Nat. Biotechnol. 28 2010 256 263
49. B. Ravikumar et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat. Genet. 36 2004 585 595
50. S. Sarkar et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies Cell Death Differ. 16 2009 46 56
51. B. Ravikumar et al. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy Hum. Mol. Genet. 12 2003 985 994
52. M. Degtyarev et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents J. Cell Biol. 183 2008 101 116
53. A. Bommareddy et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells Cancer Res. 69 2009 3704 3712
54. C.D. Kamat et al. Antioxidants in central nervous system diseases: preclinical promise and translational challenges J. Alzheimers Dis. 15 2008 473 493
55. B.R. Underwood et al. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease Hum. Mol. Genet. 19 2010 3413 3429
56. S. Sarkar et al. Lithium induces autophagy by inhibiting inositol monophosphatase J. Cell Biol. 170 2005 1101 1111
57. S. Sarkar et al. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin Hum. Mol. Genet. 17 2008 170 178
58. A. Williams et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway Nat. Chem. Biol. 4 2008 295 305
59. C. Rose et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease Hum. Mol. Genet. 19 2010 2144 2153
60. P.B. Gordon et al. Dependence of hepatocytic autophagy on intracellularly sequestered calcium J. Biol. Chem. 268 1993 26107 26112
61. S. Sarkar et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein J. Biol. Chem. 282 2007 5641 5652
62. L. Zhang et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen Proc. Natl. Acad. Sci. U.S.A. 104 2007 19023 19028
63. M. Jimenez-Sanchez et al. Autophagy and polyglutamine diseases Prog. Neurobiol. 97 2012 67 82
64. G. Kroemer, and B. Levine Autophagic cell death: the story of a misnomer Nat. Rev. Mol. Cell Biol. 9 2008 1004 1010
65. N.F. Bence et al. Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
66. P. Venkatraman et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins Mol. Cell 14 2004 95 104
67. P.O. Bauer, and N. Nukina Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy Autophagy 5 2009 747 748
68. L.M. Thompson et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome J. Cell Biol. 187 2009 1083 1099
69. K. Juenemann et al. Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes J. Biol. Chem. 288 2013 27068 27084
70. B. Lu et al. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance Nat. Neurosci. 16 2013 562 570
71. T. Kamitani et al. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1 J. Biol. Chem. 276 2001 46655 46660
72. K. Kito et al. NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression J. Biol. Chem. 276 2001 20603 20609
73. T. Tanaka et al. Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L J. Biol. Chem. 278 2003 32905 32913
74. M.S. Hipp et al. NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation J. Biol. Chem. 279 2004 16503 16510
75. R. Aron et al. NUB1 snubs huntingtin toxicity Nat. Neurosci. 16 2013 523 525
76. L. Pintard et al. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family EMBO J. 23 2004 1681 1687
77. S. Maerki et al. The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis J. Cell Biol. 187 2009 791 800
78. I. Sumara et al. A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating mitotic progression and completion of cytokinesis in human cells Dev. Cell 12 2007 887 900
79. D.W. Paty, and D.K. Li Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 43 1993 662 667
80. A. Chort et al. Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice Brain 136 2013 1732 1745
81. M. Martinez-Vicente et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease Nat. Neurosci. 13 2010 567 576
82. M.S. Hipp et al. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease J. Cell Biol. 196 2012 573 587
83. X. Gu et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice Neuron 64 2009 828 840
84. H. Jeong et al. Acetylation targets mutant huntingtin to autophagosomes for degradation Cell 137 2009 60 72
85. A.L. Southwell, and P.H. Patterson Antibody therapy in neurodegenerative disease Rev. Neurosci. 21 2010 273 287
86. B. Baldo et al. A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein J. Biol. Chem. 287 2012 1406 1414
87. S. Zhang et al. A genome-wide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila Genetics 184 2010 1165 1179
88. J.P. Miller et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease Neuron 67 2010 199 212
89. J. Doumanis et al. RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation PLoS ONE 4 2009 e7275
90. H.D. The, and iPSC. Consortium Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes Cell Stem Cell 11 2012 264 278
91. Z.R. Crook, and D. Housman Huntington's disease: can mice lead the way to treatment? Neuron 69 2011 423 435
92. X. William Yang, and M. Gray Mouse models for validating preclinical candidates for Huntington's disease D.C. Lo, R.E. Hughes, Neurobiology of Huntington's Disease: Applications to Drug Discovery 2011 CRC Press 165 195
93. S.H. Yang et al. Towards a transgenic model of Huntington's disease in a non-human primate Nature 453 2008 921 924
94. D. Yang et al. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs Hum. Mol. Genet. 19 2010 3983 3994
95. P.M. Switonski et al. Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II Mol. Neurobiol. 46 2012 430 466
96. L.B. Menalled, and M.F. Chesselet Mouse models of Huntington's disease Trends Pharmacol. Sci. 23 2002 32 39
97. L.B. Menalled et al. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats J. Comp. Neurol. 465 2003 11 26
98. J. Branco et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases Hum. Mol. Genet. 17 2008 376 390
99. H.R. Brignull et al. Modeling polyglutamine pathogenesis in C. elegans Methods Enzymol. 412 2006 256 282
100. J. Park et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1 Nature 498 2013 325 331
101. J.P. Miller et al. A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease PLoS Genet. 8 2012 e1003042
102. M.R. Sarantos et al. Pizotifen activates ERK and provides neuroprotection in vitro and in vivo in models of Huntington's disease J. Huntingtons Dis. 1 2012 195 210
103. R.P. Mason et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease Nat. Genet. 45 2013 1249 1254
104. A. Weiss et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease Anal. Biochem. 395 2009 8 15
105. X. Zhang et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo Proc. Natl. Acad. Sci. U.S.A. 102 2005 892 897
106. M. Banez-Coronel et al. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity PLoS Genet. 8 2012 e1002481
107. M.C. An et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells Cell Stem Cell 11 2012 253 263